Qurient Co., Ltd. (KOSDAQ:115180)

South Korea · Delayed Price · Currency is KRW

19,690

-1,610 (-7.56%)

At close: Jun 26, 2026

63.67% (1Y)

Market Cap	959.68B +144.9%
Revenue (ttm)	7.00B -22.1%
Net Income	-31.77B
EPS	-895.19
Shares Out	40.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	136,278
Open	21,350
Previous Close	21,300
Day's Range	19,190 - 21,500
52-Week Range	9,520 - 62,900
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Qurient

Qurient Co., Ltd., a biotech company, engages in the research and development of drugs to address unmet medical needs in Korea and internationally. The company’s pipeline products include Q301, a topical 5LO inhibitor, which is in Phase II clinical trial for the treatment of atopic dermatitis; and Telacebec (Q203), Cyt bc1 Inhibitor, that is in Phase II to treat Mycobacterial Infections, such as tuberculosis/non-TBM. Its pipeline products also comprise Adrixetinib (Q702), an Axl/Mer/CSF1R Inhibitor, which completed phase I for the treatment of ... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2008

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 115180

Full Company Profile

Financial Performance

In 2025, Qurient's revenue was 6.98 billion, a decrease of -23.94% compared to the previous year's 9.18 billion. Losses were -30.12 billion, 24.9% more than in 2024.

Financial Statements